Effect and mechanisms of Xinbao pill in the treatment of brain injury after cardiopulmonary resuscitation on Multi-Omics Technologies

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086690

Enrollment

Unknown

Registered

2024-07-09

Start date

2024-07-15

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest

Interventions

experimental group:received an additional therapy with Xinbao Pill on the basis of post-cardiac arrest syndrome (PCAS) management. The Xinbao Pill regimen involves a dosage of 360 mg (6 pills) per a

control group:add Xinbao Pill placebo treatment on the basis of the treatment of post-cardiac arrest syndrome, and the dose, frequency and course of placebo were the same as those of the experimental

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. In-hospital/pre-hospital cardiac arrest; 2. Aged 18-85 years old; 3. Patients with return of spontaneous circulation (ROSC) that is sustained for = 20 minutes; 4. Glasgow coma score = 8 after ROSC, and before sedation (if any); 5. The legal representative signed the informed consent; 6. Advanced life support is conducted.

Exclusion criteria

Exclusion criteria: 1. No-flow time >10 min (time from collapse to initiation of external cardiac massage); 2. Low-flow time >60 min (time from initiation of external cardiac massage to ROSC); 3. Cardiac arrest caused by advanced tumor and other end-of-state diseases; 4. Cardiac arrest caused by an irreversible cause (such as severe trauma and poisoning); 5. Known to be allergic to treatment; 6. Ppregnant or lactating women; 7. Patients with glaucoma; 8. Patients whose heart, brain and other functions that cannot be reversed.

Design outcomes

Primary

Measure	Time frame
survival with a favorable neurological outcome;APACHE II;	—

Secondary

Measure	Time frame
neuron-specific enolase;GCS score;CPC score;Middle cerebral artery systolic blood flow velocity (Vs), diastolic blood flow velocity (Vd), mean blood flow velocity (Vm), resistance index (RI), pulsation index (PI);SOFA score;Total length of hospital stay and ICU length of stay;Survival rate;	—

Countries

China

Contacts

Public ContactDing Banhan

Guangdong Provincial Hospital of Chinese Medicine

13682238225@139.com+86 136 8223 8225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026